Emmaus Life Sciences, Inc. Quarterly report [Sections 13 or 15(d)]

Selected Financial Statement - Liabilities - Additional Information (Details) - USD ($)			3 Months Ended
	Jul. 12, 2017	Jun. 12, 2017	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Summary Of Significant Accounting Policy [Line Items]
Accounts payables outstanding			$ 5,810,000		$ 5,979,000
API Supply Agreement [Member] \| Telcon, Inc. ("Telcon") [Member]
Summary Of Significant Accounting Policy [Line Items]
Proceeds from supply agreement		$ 31,800,000
API Supply Agreement [Member] \| Telcon, Inc. ("Telcon") [Member] \| PGLG [Member]
Summary Of Significant Accounting Policy [Line Items]
PGLG, purchase price			0	$ 0
Accounts payables outstanding			$ 1,100,000		$ 1,100,000
Revised API Agreement [Member] \| Telcon, Inc. ("Telcon") [Member]
Summary Of Significant Accounting Policy [Line Items]
Annual purchase target amount	$ 5,000,000
Target profit	$ 2,500,000